These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23110309)

  • 101. Improving the outlook for TP53-aberrant CLL.
    Choi MY
    Blood; 2021 Nov; 138(19):1785-1786. PubMed ID: 34762129
    [No Abstract]   [Full Text] [Related]  

  • 102.
    Catherwood MA; Wren D; Chiecchio L; Cavalieri D; Donaldson D; Lawless S; ElHassadi E; Hayat A; Cahill MR; O'Shea D; Sargent J; Stewart P; Maurya M; Quinn J; Murphy P; de Castro DG; Mills K; Cross NCP; Forconi F; Iyengar S; Schuh A; Thornton P
    Front Oncol; 2022; 12():909615. PubMed ID: 35837095
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Landscape of TP53 Alterations in Chronic Lymphocytic Leukemia
    Soussi T; Baliakas P
    Front Oncol; 2022; 12():808886. PubMed ID: 35251978
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution.
    Rodriguez-Meira A; Norfo R; Wen S; Chédeville AL; Rahman H; O'Sullivan J; Wang G; Louka E; Kretzschmar WW; Paterson A; Brierley C; Martin JE; Demeule C; Bashton M; Sousos N; Moralli D; Subha Meem L; Carrelha J; Wu B; Hamblin A; Guermouche H; Pasquier F; Marzac C; Girodon F; Vainchenker W; Drummond M; Harrison C; Chapman JR; Plo I; Jacobsen SEW; Psaila B; Thongjuea S; Antony-Debré I; Mead AJ
    Nat Genet; 2023 Sep; 55(9):1531-1541. PubMed ID: 37666991
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Differences in Antioxidant and Lipid Handling Protein Expression Influence How Cells Expressing Distinct Mutant TP53 Subtypes Maintain Iron Homeostasis.
    Cardona CJ; Hermann ER; Kouplen KN; Hartson SD; Montgomery MR
    Cells; 2022 Jun; 11(13):. PubMed ID: 35805147
    [TBL] [Abstract][Full Text] [Related]  

  • 106. A p53 transcriptional signature in primary and metastatic cancers derived using machine learning.
    Keshavarz-Rahaghi F; Pleasance E; Kolisnik T; Jones SJM
    Front Genet; 2022; 13():987238. PubMed ID: 36134028
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study.
    Schetelig J; Hoek J; Stilgenbauer S; Middeke JM; Andersen NS; Fox CP; Lenhoff S; Volin L; Shimoni A; Schroyens W; van Gelder M; Bunjes D; van Biezen A; Baldauf H; de Wreede LC; Tournilhac O; Kröger N; Yakoub-Agha I; Dreger P
    Bone Marrow Transplant; 2022 Jan; 57(1):144. PubMed ID: 34773090
    [No Abstract]   [Full Text] [Related]  

  • 108. CLL pathogenesis: novel microRNA/ TP53 feedback circuitry.
    Hutchinson L
    Nat Rev Clin Oncol; 2011 Mar; 8(3):125. PubMed ID: 21480561
    [No Abstract]   [Full Text] [Related]  

  • 109. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
    Hallek M
    Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Relevance of TP53 for CLL diagnostics.
    Catherwood MA; Gonzalez D; Donaldson D; Clifford R; Mills K; Thornton P
    J Clin Pathol; 2019 May; 72(5):343-346. PubMed ID: 30712002
    [No Abstract]   [Full Text] [Related]  

  • 111. Small Non-Coding RNAs in Leukemia.
    Balatti V; Croce CM
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158777
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing.
    Schuh A; Dreau H; Knight SJL; Ridout K; Mizani T; Vavoulis D; Colling R; Antoniou P; Kvikstad EM; Pentony MM; Hamblin A; Protheroe A; Parton M; Shah KA; Orosz Z; Athanasou N; Hassan B; Flanagan AM; Ahmed A; Winter S; Harris A; Tomlinson I; Popitsch N; Church D; Taylor JC
    Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29610388
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia.
    Fabris S; Mosca L; Todoerti K; Cutrona G; Lionetti M; Intini D; Matis S; Colombo M; Agnelli L; Gentile M; Spriano M; Callea V; Festini G; Molica S; Lambertenghi Deliliers G; Morabito F; Ferrarini M; Neri A
    Genes Chromosomes Cancer; 2008 Sep; 47(9):781-93. PubMed ID: 18521849
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
    Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
    Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
    Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
    Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
    [TBL] [Abstract][Full Text] [Related]  

  • 116. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.
    Shindiapina P; Brown JR; Danilov AV
    Br J Haematol; 2014 Oct; 167(2):149-61. PubMed ID: 25040077
    [TBL] [Abstract][Full Text] [Related]  

  • 117. The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes on chromosome 17p.
    Lin K; Lane B; Carter A; Johnson GG; Onwuazor O; Oates M; Zenz T; Stilgenbauer S; Atherton M; Douglas A; Ebrahimi B; Sherrington PD; Pettitt AR
    Br J Haematol; 2013 Jan; 160(1):53-62. PubMed ID: 23110309
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
    Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
    Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
    [TBL] [Abstract][Full Text] [Related]  

  • 119.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 120.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.